This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ertugliflozin and Sitagliptin Fixed Dose Combo
Merck & Co., Inc.
Drug Names(s): Ertugliflozin and Sitagliptin, ertugliflozin and Januvia, Ertugliflozin/Sitagliptin
Deal Structure: Pfizer and MerckIn April 2013, Merck and Pfizer entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizers ertugliflozin (PF-04971729) being evaluated for the treatment of type 2 diabetes. Under the terms of the agreement, Merck, through a subsidiary, and Pfizer will collaborate on the clinical development and commercialization of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and JANUVIA (sitagliptin) tablets. Merck will continue to retain the rights to its existing portfolio of sitagliptin-containing products. Pfizer has received an upfront payment and milestones of $60 million and will be eligible for additional payments associated with the achievement of pre-specified future clinical, regulatory and commercial milestones. Merck and Pfizer will share potential revenues and certain costs on a 60/40 percent basis.
Partners: Pfizer Inc.
Ertugliflozin and Sitagliptin Fixed Dose Combo News
Additional information available to subscribers only: